AUS
NZ
UK
CA
USA
IND
Healthcare
Imugene Secures Major Capital Boost to Advance Clinical Trials
December 24, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,- Imugene extends cash runway to late 2025 through strategic capital injection.,- Funding supports clinical trials for key programs, including azer-cel and VAXINIA.,- Additional cost-saving measures strengthen financial position.,Imugene (...
Avita Medical's Spray-On Skin Device Earns FDA Approval
December 24, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,- Avita Medical (AVH) receives FDA approval for RECELL GO Mini, expanding its advanced wound care solutions.,- The new Mini GO device targets smaller wounds, enhancing resource efficiency and flexibility for clinicians.,- Avita plans to in...
Polynovo's Record Sales Drive ASX Momentum Amid Market Recovery
December 23, 2024 02:55 PM AEDT| By Team Kalkine MediaHighlights:,Polynovo,(PNV) surged on record-breaking monthly sales.,ASX recovered from last week’s technical disruptions to open on time.,Real Estate, Financials, and Consumer Discretionary sectors lead ASX gains.,The Australian Securities Exchange (...
PolyNovo Achieves Record $10.1M Monthly Sales in November 2024
December 23, 2024 01:12 PM AEDT| By Team Kalkine MediaHighlights,Record Monthly Sales:,PolyNovo reported,$10.1M,in unaudited sales for November 2024, marking the company's highest monthly performance to date.,Geographic Expansion:,United States:,November sales reached,$7.0M,, contributing to year-to-dat...
Rhythm Biosciences Acquires Genetype Business from Genetic Technologies
December 23, 2024 12:34 PM AEDT| By Team Kalkine MediaHighlights,Strategic Acquisition:,Rhythm Biosciences has entered into an Asset Sale Agreement (ASA) with the administrators of Genetic Technologies Ltd (GTG) to acquire the Genetype business, a leader in genetic risk assessment for cancers.,Transacti...
Prescient Therapeutics Shares Surge 24% on FDA Approval for PTX-100 Phase 2 Trial
December 23, 2024 11:41 AM AEDT| By Team Kalkine MediaHighlights,FDA Clears Phase 2 IND:,The U.S. FDA has approved Prescient Therapeutics' Investigational New Drug (IND) application for its Ras pathway inhibitor, PTX-100, targeting advanced cutaneous T-cell lymphomas (r/r CTCL).,Strong Phase 1b Results:...
Pro Medicus Shares Rise Following AU$30 Million Contract with Duly Health and Care
December 23, 2024 10:59 AM AEDT| By Team Kalkine MediaHighlights,AU$30 Million Contract Signed:,Pro Medicus secures a seven-year deal with Duly Health and Care, the largest physician-directed medical group in the U.S. Midwest.,Cloud-Based Imaging Platform Rollout:,The deal includes implementing Pro Medi...
FDA Clears Prescient Therapeutics (ASX:PTX) for Phase 2 PTX-100 Trial Targeting T-Cell Lymphomas
December 23, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,Prescient Therapeutics (PTX) receives FDA clearance for a Phase 2 trial of PTX-100.,The trial focuses on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL).,Phase 1b data showed promising safety and response rates for PTX-100.,P...
Pro Medicus Expands U.S. Presence with $30m Deal
December 23, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (PME) secures a long-term partnership with Duly Health and Care.,The $30m agreement focuses on implementing advanced cloud imaging solutions.,The new system replaces legacy technologies across DHC's expansive operations.,Pro Me...
Integral Diagnostics Completes Merger with Capitol Health, Appoints New Directors, and Refinances Debt
December 20, 2024 02:28 PM AEDT| By Team Kalkine MediaHighlights,Merger Completion:,Integral Diagnostics (ASX: IDX) has completed its merger with Capitol Health (ASX: CAJ) through a scheme of arrangement.,Scheme Consideration:,Capitol shareholders received 0.12849 Integral shares for each Capitol share...
Little Green Pharma to Acquire Health House Australia for AU$1.25Mn
December 20, 2024 02:14 PM AEDT| By Team Kalkine MediaHighlights,Strategic Acquisition:,Little Green Pharma signs a binding letter of intent to acquire Health House Australia Pty Ltd for $1.25 million.,Revenue Boost:,Health House, a cashflow breakeven business, generates $7.5 million in annual revenue.,...
Radiopharm Theranostics Advances with Phase 1 Cancer Trial Approval
December 20, 2024 01:51 PM AEDT| By Team Kalkine MediaHighlights,Radiopharm,Theranostics,(RAD) secures ethics approval for a Phase 1 cancer trial,.,The trial targets HER2-positive cancers using the novel 177Lu-RAD202 therapy,.,Lutetium-177 isotope aims to deliver localized radiation with minimal side ef...
Radiopharm Theranostics Receives Approval for Lu-RAD202 Clinical Trials
December 20, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,Radiopharm Theranostics Ltd (ASX:RAD) has gained ethics approval to commence Phase 1 trials for Lu-RAD202, a candidate treatment for HER2-positive breast and gastric cancers.,The trial will assess the safety and initial clinical activity o...
Mesoblast (ASX:MSB) Gains Momentum with FDA Approval for Ryoncil Therapy
December 19, 2024 06:16 PM AEDT| By Team Kalkine MediaHighlights,FDA approval boosts Mesoblast (MSB) with new therapy Ryoncil.,Ryoncil marks the first approved therapy for SR-aGvHD in the US.,Mesoblast secures strong market positioning for innovative cell therapy.,Biotech company Mesoblast (ASX:MSB) wit...
Mesoblast's (ASX:MSB) Ryoncil Secures Historic FDA Approval for SR-aGvHD
December 19, 2024 03:12 PM AEDT| By Team Kalkine MediaHighlights,Ryoncil,becomes the first FDA-approved mesenchymal stromal cell therapy for SR-,aGvHD,.,Mesoblast (,ASX:MSB,) expands treatment options for children with severe graft-versus-host disease,.,The company to debut on the Nasdaq Biotechnology I...
Breakthrough: Mesoblast (ASX:MSB) Gains FDA Approval for First MSC Therapy in the US
December 19, 2024 01:54 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast (MSB) secures FDA approval for RYONCIL®,.,RYONCIL,becomes,the first mesenchymal stromal cell therapy approved in the US,.,Significant impact,anticipated,for pediatric graft-versus-host disease treatment,.,Mesoblast (ASX:MSB) has...
Austco Healthcare Limited (ASX:AHC): Examining Performance Metrics Amid Market Dynamics
December 19, 2024 12:25 PM AEDT| By Team Kalkine MediaHighlights:,Austco Healthcare Limited (,ASX:AHC,) has a price-to-earnings (P/E) ratio of 13.9x, significantly lower than the broader Australian market average.,The company has shown strong earnings growth, including a 198% gain in the last year and a...
LTR Pharma Partners with Men’s Health Downunder for Erectile Dysfunction Nasal Spray Rollout
December 19, 2024 12:12 PM AEDT| By Team Kalkine MediaHighlights,LTR Pharma partners with MHDU to introduce SPONTAN, a nasal spray for erectile dysfunction.,Collaboration provides access to MHDU’s extensive referral network, including GPs, urologists, and sexual health clinics.,Real-world patient data c...
Mesoblast Shares Surge 33% as FDA Approves Groundbreaking RYONCIL® Therapy
December 19, 2024 12:07 PM AEDT| By Team Kalkine MediaHighlights,FDA approves Mesoblast’s RYONCIL® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy in the U.S.,RYONCIL becomes the only approved treatment for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.,Meso...
Orthocell (ASX:OCC) Advances Nerve Repair Innovation with FDA Submission for Remplir™
December 19, 2024 11:21 AM AEDT| By Team Kalkine MediaHighlights,Orthocell,(OCC),submits,FDA application for,Remplir,™, targeting the expansive US nerve repair market,.,Successful study positions,Remplir,™ as a safe and effective solution for peripheral nerve repair,.,Company prepares for US launch, sup...
Advertise your brand on Kalkine Media